Brian A. Millen

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

Vladimir Skljarevski, Manjit Matharu, Brian A. Millen et al. · Cephalalgia · 2018 · 557 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

Bruce J. Kinon, Lu Zhang, Brian A. Millen et al. · Journal of Clinical Psychopharmacology · 2011 · 257 citations

Medicine, Pharmacology, Psychiatry +17

Trial of Galcanezumab in Prevention of Episodic Cluster Headache

Peter J. Goadsby, David W. Dodick, Massimo Leone et al. · New England Journal of Medicine · 2019 · 255 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

Bruce J. Kinon, Brian A. Millen, Lu Zhang et al. · Biological Psychiatry · 2015 · 167 citations

Medicine, Pharmacology, Psychiatry +14

Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

Virginia L. Stauffer, Brian A. Millen, Scott W. Andersen et al. · Schizophrenia Research · 2013 · 131 citations

Pharmacy, Pharmacotherapy, Psychiatry +14